title: Perimount bovine pericardial valve to restore pulmonary valve competence late after right ventricular outflow tract repair.
abstract: OBJECTIVE
  No ideal option exists for restoring pulmonary valve competence late after repair of the congenitally abnormal right ventricular outflow tract (RVOT). This has driven a continued search for new alternatives. Texas Children's Hospital has recently used the Carpentier-Edwards Perimount RSR Pericardial Aortic Prosthesis (Edwards Lifesciences, Irvine, Calif, USA) for this indication and reports the initial experience.
  
  
  METHODS
  Retrospective chart review.
  
  
  METHODS
  Academically affiliated tertiary-care pediatric hospital.
  
  
  METHODS
  Twenty-six patients who underwent pulmonary valve replacement with the Perimount valve late after RVOT reconstruction between June 2002 and November 2005.
  
  
  METHODS
  No prospective interventions.
  
  
  METHODS
  Hospital morbidity and mortality. Valve function assessed by follow-up visits and echocardiograms.
  
  
  RESULTS
  Mean age and weight of the patients were 20.3 +/- 9.8 years (range 7.0-45.1 years) and 56.2 +/- 18.1 kg (range 35.8-109 kg). Twenty-two patients (85%) had severe pulmonary insufficiency (PI), 23 (89%) had symptomatic right heart failure, and 14 (54%) had moderate to severe right ventricular dysfunction. Average prosthetic valve size was 23 mm (range 19-27 mm). Twenty-one (88%) patients were extubated within 24 hours. There was no hospital mortality. Median length of stay for all patients from day of surgery was 6 days (range 3-56 days). Median length of last echocardiography follow-up was 12.4 months (range 0.1-37.6 months). At that time, 16 of the 26 (62%) patients had improved right ventricular function, no patient demonstrated significant RVOT obstruction, and 24 patients (92%) have no PI or mild PI. Freedom from death, reintervention, or reoperation on the pulmonary valve is 100% at 2.5 years.
  
  
  CONCLUSIONS
  Initial results with the Perimount bovine pericardial tissue prosthesis for pulmonary valve replacement are encouraging. Further follow-up is required to define long-term function and durability.
authors: Michael E. DeBakey Department of Surgery, Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX 77030, USA. dlmorale@texaschildrenshospital.org
authors: David L S
authors: DL
authors: Morales
authors: Brandi E
authors: BE
authors: Braud
authors: Daniel J
authors: DJ
authors: DiBardino
authors: Kathleen E
authors: KE
authors: Carberry
authors: E Dean
authors: ED
authors: McKenzie
authors: Jeffrey S
authors: JS
authors: Heinle
authors: Charles D
authors: CD
authors: Fraser
mesh_terms: D000818:Animals; D001021:Aortic Valve; D001705:Bioprosthesis; D002417:Cattle; D015331:Cohort Studies; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D007902:Length of Stay; D010496:Pericardium; D011664:Pulmonary Valve / Q000503:physiopathology / Q000601:surgery*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014694:Ventricular Outflow Obstruction / Q000503:physiopathology* / Q000601:surgery*